Novel therapies and vaccines against the human respiratory syncytial virus

Expert Opinion on Investigational Drugs

Volumn 24, Issue 12, 2015, Pages 1613-1630

  Rivera, Claudia A ^a   Gómez, Roberto S ^a   Díaz, Rodrigo A ^a   Céspedes, Pablo F ^a   Espinoza, Janyra A ^a   González, Pablo A ^a   Riedel, Claudia A ^b   Bueno, Susan M ^a,c   Kalergis, Alexis M ^a,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c INSERM   (France)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

antibody therapy; hRSV; T cell immunity; vaccines

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; VIROSOME; VIRUS PROTEIN; VIRUS VACCINE; ANTIVIRUS AGENT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENTARITY DETERMINING REGION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG DESIGN; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; MATERNAL WELFARE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; PROTEIN CONFORMATION; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS ATTENUATION; VIRUS LIKE AGENT; AGED; ANIMAL; IMMUNOCOMPROMISED PATIENT; INFANT; ISOLATION AND PURIFICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

AGED; ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 84949201815     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1099626     Document Type: Review

References (131)

1. Baker KA, Ryan ME. RSV infection in infants and young children. What's new in diagnosis, treatment, and prevention? Postgrad Med. 1999;106(7):97-9, 103-4, 107-8 passim.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375 (9725):1545-1555.
3. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. Pediatric Pharmacol Ther. 2009;14 (2):75-85.
4. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57 (8):1069-1077.
5. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011;162(1-2):80-99.
6. Batonick M, Wertz GW. Requirements for human respiratory syncytial virus glycoproteins in assembly and egress from infected cells. Adv Virol. 2011;2011:1-11.
7. Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol. 1999;73(8):6610-6617.
8. Gan SW, Tan E, Lin X, et al. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem. 2012;287(29):24671-24689.
9. Tan L, Coenjaerts FE, Houspie L, et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol. 2013;87 (14):8213-8226.
10. Bueno SM, Gonzalez PA, Pacheco R, et al. Host immunity during RSV pathogenesis. Int Immunopharmacol. 2008;8(10):1320-1329.
11. Cespedes PF, Bueno SM, Ramirez BA, et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci USA. 2014;111(31):E3214-23.
12. Gonzalez PA, Carreno LJ, Bueno SM, et al. Understanding respiratory syncytial virus infection to improve treatment and immunity. Curr Mol Med. 2013;13 (7):1122-1139.
13. Palgen JL, Jurgens EM, Moscona A, et al. Unity in diversity: shared mechanism of entry among paramyxoviruses. Prog Mol Biol Transl Sci. 2015;129:1-32.
14. Munday DC, Wu W, Smith N, et al. Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis. J Virol. 2015;89(2):917-930.
15. Lotz MT, Peebles RS Jr. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep. 2012;12(5):380-387.
16. Shaikh FY, Utley TJ, Craven RE, et al. Respiratory syncytial virus assembles into structured filamentous virion particles independently of host cytoskeleton and related proteins. PLoS One. 2012;7(7): e40826.
17. Lukens MV, Kruijsen D, Coenjaerts FE, et al. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J Virol. 2009;83(14):7235-7243.
18. Lay MK, Bueno SM, Galvez N, et al. New insights on the viral and host factors contributing to the airway pathogenesis caused by the respiratory syncytial virus. Crit Rev Microbiol. 2015;29:1-13.
19. Lay MK, Gonzalez PA, Leon MA, et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect. 2013;15(3):230-242.
20. Guerrero-Plata A, Kolli D, Hong C, et al. Subversion of pulmonary dendritic cell function by paramyxovirus infections. J Immunol. 2009;182(5):3072-3083.
21. Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA. 2008;105(39):14999-15004.
22. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33 (2):235-252.
23. de Almeida Nagata DE, Demoor T, Ptaschinski C, et al. IL-27R-mediated regulation of IL-17 controls the development of respiratory syncytial virus-associated pathogenesis. Am J Pathol. 2014;184(6):1807-1818.
24. Roman M, Calhoun WJ, Hinton KL, et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med. 1997;156(1):190-195.
25. Freitas GR, Silva DA, Yokosawa J, et al. Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children. J Med Virol. 2011;83(10):1826-1833.
26. Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191 (9):1040-1049.
27. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190 (2):373-378.
28. Court SD. Epidemiology and natural history of respiratory infections in children. J Clin Pathol Suppl. 1968;2:30-37.
29. Ohuma EO, Okiro EA, Ochola R, et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol. 2012;176 (9):794-802.
30. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-434.
31. Knudson CJ, Hartwig SM, Meyerholz DK, et al. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog. 2015;11(3):e1004757.
32. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41.
33. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859-865.
34. Gomez RS, Guisle-Marsollier I, Bohmwald K, et al. Respiratory syncytial virus: pathology, therapeutic drugs and prophylaxis. Immunol Lett. 2014;162(1 Pt A):237-247.
35. Walsh EE, Hruska JF. Identification of the virus-specific proteins of respiratory syncytial virus temperature-sensitive mutants by immunoprecipitation. Proc Soc Exp Biol Med. 1983;172(2):202-206.
36. Tayyari F, Marchant D, Moraes TJ, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011;17(9):1132-1135.
37. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176 (5):1215-1224.
38. Embleton ND, Harkensee C, McKean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed. 2005;90(4):F286-9.
39. Harkensee C, Brodlie M, Embleton ND, et al. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect. 2006;52(1):2-8.
40. Fenton C, Scott LJ, Plosker GL. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatric Drugs. 2004;6 (3):177-197.
41. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531-537.
42. Wu H, Pfarr DS, Tang Y, et al. Ultrapotent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126-144.
43. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultrapotent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652-665.
44. Mejias A, Chavez-Bueno S, Rios AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother. 2005;49 (11):4700-4707.
45. Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in atrisk children. Pediatric Infect Dis J. 2009;28(4):267-272.
46. Lagos R, DeVincenzo JP, Munoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatric Infect Dis J. 2009;28 (9):835-837.
47. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35-51.
48. Fernandez P, Trenholme A, Abarca K, et al. A phase 2, randomized, doubleblind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatrics. 2010;10:38.
49. Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatric Res. 2011;70(2):186-191.
50. Ramilo O, Lagos R, Saez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatric Infect Dis J. 2014;33(7):703-709.
51. Dall'Acqua WF, Cook KE, Damschroder MM, et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006;177(2):1129-1138.
52. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147-6153.
53. McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340 (6136):1113-1117.
54. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93-99.
55. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994;169(6):1368-1373.
56. Schepens B, Ibanez LI, De Baets S, et al. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692-1701.
57. Hultberg A, Temperton NJ, Rosseels V, et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One. 2011;6(4):e17665.
58. Ackermann MR. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J. 2014;55(1):4-15.
59. Han J, Takeda K, Wang M, et al. Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection. Am J Respir Cell Mol Biol. 2014;51(1):143-154.
60. Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis. 2009;200(3):439-447.
61. Anderson LJ, Dormitzer PR, Nokes DJ, et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013;31(Suppl 2):B209-15.
62. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cellderived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013;31(3):524-532.
63. Raghunandan R, Lu H, Zhou B, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine. 2014;32(48):6485-6492.
64. Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7(11):e50852.
65. Lambert SL, Aslam S, Stillman E, et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLASE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One. 2015;10(3): e0119509.
66. Cherukuri A, Patton K, Gasser RA Jr., et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol. 2013;20 (2):239-247.
67. Cusi MG, Martorelli B, Di Genova G, et al.. Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects. Immun Ageing. 2010;7:14.
68. Broadbent L, Groves H, Shields MD, et al. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses. 2015;9(4):169-178.
69. Garg R, Latimer L, Simko E, et al. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. J Gen Virol. 2014;95(Pt 2):301-306.
70. Garg R, Latimer L, Gerdts V, et al. The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies. Vaccine. 2015;33(11):1338-1344.
71. Zhan X, Hurwitz JL, Krishnamurthy S, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine. 2007;25(52):8782-8793.
72. Jones BG, Sealy RE, Rudraraju R, et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine. 2012;30(5):959-968.
73. Jones BG, Sealy RE, Surman SL, et al. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine. 2014;32(26):3264-3273.
74. Lee YN, Hwang HS, Kim MC, et al. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology. 2015;476:217-225.
75. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med. 1994;179(1):81-89.
76. Cheon IS, Shim BS, Park SM, et al. Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf). PLoS One. 2014;9(4):e94269.
77. Chirkova T, Boyoglu-Barnum S, Gaston KA, et al. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol. 2013;87(24):13466-13479.
78. Jorquera PA, Choi Y, Oakley KE, et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. Plos One. 2013;8(9):e74905.
79. Roux X, Dubuquoy C, Durand G, et al. Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PloS one. 2008;3(3):e1766.
80. Sawada A, Komase K, Nakayama T. AIKC measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine. 2011;29(7):1481-1490.
81. Yamaji Y, Nakayama T. Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine. 2014;32(35):4529-4536.
82. Espinoza JA, Bueno SM, Riedel CA, et al. Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design. Immunology. 2014;143(1):1-12.
83. Dennehy M, Bourn W, Steele D, et al. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. Vaccine. 2007;25(18):3646-3657.
84. Fennelly GJ, Flynn JL, Ter Meulen V, et al. Recombinant bacille Calmette-Guerin priming against measles. J Infect Dis. 1995;172(3):698-705.
85. Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA. 2008;105(52):20822-20827.
86. Cautivo KM, Bueno SM, Cortes CM, et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol. 2010;185(12):7633-7645.
87. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389(5):521-536.
88. Morrison TG, Walsh EE. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:285-306.
89. Quan FS, Kim Y, Lee S, et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis. 2011;204(7):987-995.
90. Lee S, Quan FS, Kwon Y, et al. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res. 2014;111:129-135.
91. McGinnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol. 2011;85 (1):366-377.
92. Schmidt MR, McGinnes LW, Kenward SA, et al. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol. 2012;86 (21):11654-11662.
93. Wilschut J. Influenza vaccines: the virosome concept. Immunol Lett. 2009;122 (2):118-121.
94. Moser C, Muller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Exp Rev Vacc. 2013;12 (7):779-791.
95. Shafique M, Meijerhof T, Wilschut J, et al. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS One. 2013;8(4):e61287.
96. Kamphuis T, Meijerhof T, Stegmann T, et al. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812.
97. Kamphuis T, Stegmann T, Meijerhof T, et al. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses. 2013;7 (6):1227-1236.
98. Luongo C, Winter CC, Collins PL, et al. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol. 2013;87(4):1985-1996.
99. Meng J, Lee S, Hotard AL, et al. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. mBio. 2014;5(5):e01704-14.
100. Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005;79 (14):9315-9319.
101. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191 (7):1093-1104.
102. Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and nonpermissive temperatures. Virus Res. 2012;169(1):38-47.
103. Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSVseronegative children 5 to 24 months of age. PLoS One. 2013;8(10):e77104.
104. American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
105. Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015;28 (3):221-224.
106. Kaaijk P, Luytjes W, Rots NY. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vacc Immunother. 2013;9(6):1263-1267.
107. Kwon YM, Hwang HS, Lee JS, et al. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res. 2014;104:1-6.
108. Stensballe LG, Ravn H, Kristensen K, et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr. 2009;154(2):296-298.
109. Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol. 1986;24 (5):894-898.
110. Murphy BR, Olmsted RA, Collins PL, et al. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol. 1988;62(10):3907-3910.
111. Shinoff JJ, O'Brien KL, Thumar B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008;198(7):1007-1015.
112. Mejias A, Ramilo O. New options in the treatment of respiratory syncytial virus disease. J Infect. 2015;71(Suppl 1):S80-7.
113. Ventre K, Randolph A. WITHDRAWN: ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2010;5:CD000181.
114. Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics. 1997;99(3):E7.
115. Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol. 2003;77(9):5054-5064.
116. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711-722.
117. Bond S, Draffan AG, Fenner JE, et al. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a] isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. Bioorg Med Chem Lett. 2015;25(4):976-981.
118. Wyde PR, Laquerre S, Chetty SN, et al. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005;68(1):18-26.
119. Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007;51(9):3346-3353.
120. Tiong-Yip CL, Aschenbrenner L, Johnson KD, et al. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother. 2014;58 (7):3867-3873.
121. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008;77(3):225-231.
122. Sun Z, Pan Y, Jiang S, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses. 2013;5(1):211-225.
123. Noton SL, Nagendra K, Dunn EF, et al. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol. 2015;89 (15):7786-7798.
124. Cass L, Ito K, Charron C, et al. RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus. Eur Res J. 2013;42(Suppl 57):1970.
125. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107(19):8800-8805.
126. Williams JV, Weitkamp JH, Blum DL, et al. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol Immunol. 2009;47(2-3):407-414.
127. Rothoeft T, Fischer K, Zawatzki S, et al. Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus. Clin Exp Immunol. 2007;150 (2):263-273.
128. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol. 1999;163(4):2249-2255.
129. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Exp Rev Clin Immunol. 2014;10 (9):1171-1184.
130. Espinoza JA, Bohmwald K, Cespedes PF, et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci USA. 2013;110(22):9112-9117.
131. Coe JE, Prince GA. Definition of cotton rat immunoglobulins: sigmodon species differ in expression of IgG isotypes and production of respiratory syncytial virus antibody. Immunology. 1996;88 (3):323-330.